Age 18 to 63 years of age; severe patchy hair loss from alopecia areata
This study is testing an oral, experimental drug called upadacitinib for the treatment of alopecia areata (AA). The purpose of this study is to assess how safe, effective, and tolerable upadacitinib is in adult participants with severe AA.
You may qualify to participate in this study if you:* – Are 18 to 63 years of age – Have severe patchy hair loss from alopecia areata – Have not been diagnosed with other types of hair loss (including male or female pattern baldness) *There are additional requirements as determined by a screening process.
If you qualify for the study, you will receive oral tablets of either upadacitinib or placebo once daily for up to 160 weeks, with the potential of being re-randomized into a different treatment group at Weeks 24 and 52. A placebo is a substance that looks like the investigational drug but contains no active ingredients. Participants will be followed up for up to 30 days after last study drug dose.
Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
This study is taking place at locations throughout the United States. For more information on the study, visit clincialtrials.gov.
